Clinical features of the patients analyzed in this study
| Characteristic . | Category . | |||
|---|---|---|---|---|
| LTR post-SCT/DLI . | Early post-SCT . | IM-treated . | Total . | |
| No. of patients | 9 | 3 | 5 | 17 |
| Median age at diagnosis, y (range) | 34 (24-43) | 32 (22-32) | 41 (38-56) | 34 (22-56) |
| Patient sex | ||||
| Female | 3 | 0 | 4 | 7 |
| Male | 6 | 3 | 1 | 10 |
| Median duration of IM therapy,* mo (range) | NA | NA | 76 (63-79) | NA |
| Donor | ||||
| Sibling | 4 | 1 | NA | 5 |
| VUD | 3 | 2 | NA | 5 |
| Syngeneic | 2 | 0 | NA | 2 |
| DLI | 2 | 3 | NA | 5 |
| Characteristic . | Category . | |||
|---|---|---|---|---|
| LTR post-SCT/DLI . | Early post-SCT . | IM-treated . | Total . | |
| No. of patients | 9 | 3 | 5 | 17 |
| Median age at diagnosis, y (range) | 34 (24-43) | 32 (22-32) | 41 (38-56) | 34 (22-56) |
| Patient sex | ||||
| Female | 3 | 0 | 4 | 7 |
| Male | 6 | 3 | 1 | 10 |
| Median duration of IM therapy,* mo (range) | NA | NA | 76 (63-79) | NA |
| Donor | ||||
| Sibling | 4 | 1 | NA | 5 |
| VUD | 3 | 2 | NA | 5 |
| Syngeneic | 2 | 0 | NA | 2 |
| DLI | 2 | 3 | NA | 5 |
LTR indicates long-term remission; SCT, stem cell transplantation; DLI, donor lymphocyte infusion; IM, imatinib; VUD, voluntary unrelated donor; and NA, not applicable; .
Additional therapy in IM-treated patients: all 5 IM-treated patients received hydroxyurea. Only 1 of the 5 IM-treated patients received Interferon-α (IFNα) prior to IM; this patient (represented in Figure 1B, the sole patient who did not achieve gBCR-ABL negativity) was on IFNα for 32 months, reaching a minor cytogenetic response. IFNα was stopped 7 months before start of IM. This same patient also received homoharringtonine for 7 months, during months 33 to 39 of IM therapy. Of the 4 additional patients, 1 received IFNα during months 11 to 13 of IM therapy.